Immunis, Inc.
Discover how Immunis, a private biotechnology company is developing new secretome products for the treatment of age-related immune dysfunction
Funding history
About Immunis, Inc.
How much funding has Immunis, Inc. raised?
Immunis, Inc. has raised $48.2M in total funding. The most recent round was Series A.
Where is Immunis, Inc. headquartered?
Immunis, Inc. is headquartered in Laguna Beach, CA.
What does Immunis, Inc. do?
Discover how Immunis, a private biotechnology company is developing new secretome products for the treatment of age-related immune dysfunction
What problem does Immunis, Inc. solve?
Aging drives muscle loss (sarcopenia) and metabolic disease, undermining people's strength, health span, and independence.
What's Immunis, Inc.'s solution?
Immunis is a clinical-stage biotech developing IMM01-STEM, an off-the-shelf investigational biologic made of stem cell-derived regenerative factors intended to regenerate muscle and enhance muscle function.
What makes Immunis, Inc. different?
The company describes IMM01-STEM as a first-in-class 'multi-active' biologic that impacts multiple signaling pathways at once, rather than a single-target therapy, and is currently in Phase 1/2a and Phase 2 clinical trials.
What makes Immunis, Inc. notable?
Immunis is chaired by Dr. Hans Keirstead, a well-known stem cell scientist and repeat biotech entrepreneur.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 27, 2026.